Citations

Clear

6728 citation(s) found for "Li, Mark".

SARC041: A phase 3 randomized double-blind study of abemaciclib versus placebo in patients with advanced dedifferentiated liposarcoma.
Riedel, Richard F. , Riedel, Richard F , Dickson, Mark A. , Ballman, Karla V. , Weiss, Mia C. , Attia, Steven , Pollack, Seth M. , Choy, Edwin , Wagner, Andrew J. , Wilky, Breelyn A , Davis, Lara E. , Koff, Andrew, Tap, William D.

Mayo Clinic

Journal of Clinical Oncology | June 3, 2026 | Volume: 44 | Issue: 17_suppl | Pages: No page available

10.1200/jco.2026.44.17_suppl.lba2 Get It

LBA2 Background: Dedifferentiated liposarcoma (DDLS) remains a difficult disease to treat with limited systemic therapy options. Approved drugs offer modest benefit such as trabectedin (median progression-free survival [mPFS] 2.2 months [m]) or eribulin (mPFS 2.0m). The Cyclin-dependent kinase 4 (CDK4) oncogene is ubiquitously amplified in DDLS and is a rational therapeutic target. In single-arm phase 2 studies, treatment with selective CDK4 inhibitors resulted in mPFS 4.2m with palbociclib and mPFS 7.7m with abemaciclib. We hypothesized that treatment with abemaciclib would improve PFS compared to placebo in patients with recurrent or metastatic DDLS. Methods: SARC041 was a phase 3 randomized double-blind study of abemaciclib versus placebo. The study was open at 9 academic medical centers in the USA. Eligible patients (pts) had recurrent or metastatic DDLS (purely well-differentiated liposarcoma excluded), progression of disease by RECIST 1.1 in the 6 months prior to study entry, any number of prior systemic therapies, and adequate organ function and performance status. Pts were stratified by prior lines of therapy (0 vs 1 or more) and randomized 1:1 between abemaciclib 200 mg PO twice a day or matching placebo. Scans were every 6 weeks (every 12 weeks after week 36) and pts with progression of disease on placebo could cross over to open label abemaciclib. The primary endpoint was PFS. The design provided 80% power with two-sided 10% significance level to detect a hazard ratio of 0.6 by log-rank test. Secondary endpoints were overall response rate (ORR), PFS and response rate after crossover, and overall survival (OS). Data cutoff was March 1, 2026. Results: In total, 108 pts were randomized to receive abemaciclib (n = 54) or placebo (n = 54). Demographic/baseline characteristics were generally similar across treatment arms. Abemaciclib demonstrated a statistically significant improvement in PFS at 9.67m vs placebo at 1.52m (hazard ratio [HR] 0.39; 95% confidence interval [CI], 0.25–0.59; p < 0.001). ORR was 9.3% for abemaciclib vs 0% for placebo (p = 0.057). mOS was not reached with abemaciclib vs 25.45m with placebo (HR 0.55; 95% CI, 0.28–1.07; p = 0.077). mPFS after crossover from placebo to abemaciclib was 3.44m (95% CI 2.66, 6.84). ORR after crossover was 4.3% (95% CI 0.53%, 15%). mOS after crossover was 24.03m (95% CI: 11.7, NA). Grade 3 or higher adverse event rates were similar in both arms (p > 0.99). No new safety signals were observed. Conclusions: Abemaciclib demonstrated a statistically significant improvement in PFS vs placebo in pts with dedifferentiated liposarcoma, with an encouraging OS trend. These results support abemaciclib as a new treatment option for dedifferentiated liposarcoma. Clinical trial information: NCT04967521 .
Age and Procedural Timing for Asymptomatic Severe Aortic Stenosis: Analysis From the EARLY TAVR Trial
Goel, Kashish , Lindman, Brian R. , Schwartz, Allan, Cohen, DE, Giustino, Gennaro, Oldemeyer, J. Bradley , Strote, Justin, Babaliaros, Vasilis, Devireddy, Chandan , Fischbein, Michael P. , Fearon, W F, Daniels, David, Spies, Christian, Shah, Pinak , Dahle, Thom, Apostolou, Dimitrios , Makkar, R, Davidson, Charles J. , Sheth, Tej, Sorajja, Paul , DeVries, James T. , Southard, J.H., Depta, Jeremiah P. , Pop, Andrei, Rinaldi, Michael J., Badr, Salem , Russo, Mark J., Wang, Yizhuo , Leon, Martin B. , Généreux, Philippe , Cohen, David J. , Schwartz, Allan , Cohen, David Jonathan , Babaliaros, Vasilis , Devireddy, Chandan M , Fearon, William F , Chhatriwalla, Adnan K , Suradi, Hussam , Shah, Pinak , Szerlip, Molly , Dahle, Thom , Apostolou, Dimitrios , Makkar, Raj , Davidson, Charles J. , Sorajja, Paul , DeVries, James T , Southard, Jeffrey , Depta, Jeremiah P , Badr, Salem , Guerrero, Mayra E , McCabe, James M , Pibarot, Phillippe , Wang, Yizhuo , Leon, Martin B. , Généreux, Philippe , Lindman, Brian R , Giustino, Gennaro , Babaliaros, Vasilis , Fearon, William F. , Makkar, Raj , Sheth, Tej , Rinaldi, Michael , Williams, Mathew , Russo, Mark J., Guerrero, Mayra

Mayo Clinic

Circulation: Cardiovascular Interventions | June 3, 2026 | Volume: 19 | Issue: 8 | Pages: No page available

10.1161/circinterventions.125.016370 | PMID 42233211 Get It

BACKGROUND: The EARLY TAVR trial (Evaluation of TAVR Compared to Surveillance for Patients with Asymptomatic Severe Aortic Stenosis) demonstrated that early transcatheter aortic valve replacement (TAVR) was superior to clinical surveillance (CS) in asymptomatic severe aortic stenosis. The relative impact of early TAVR versus CS strategy by age is unknown. METHODS: The study population of the EARLY TAVR trial was stratified into 4 age groups: 65 to 69 years (n=141), 70 to 74 years (n=263), 75 to 79 years (n=250), and ≥80 years (n=247). Associations between age and the trial primary end point of death, stroke, or unplanned cardiovascular hospitalization; the composite end point of death, stroke, or heart failure hospitalization; and its individual components were examined. Interaction tests evaluated whether the treatment effect of early TAVR versus CS differed by age. RESULTS: No interaction was detected between age and the treatment effect of early TAVR versus CS for the composites or individual outcomes. We observed lower stroke rates with early TAVR compared with CS in the youngest (65–69 years, absolute risk reduction, 13%; P =0.008) and oldest (≥80 years; absolute risk reduction, 12.3%; P =0.029) age groups. The absolute difference in heart failure hospitalization rates between the early TAVR and CS arms at 2 years was greatest in the oldest patients (≥80 years, 9.1%; 75–79 years, 5.9%; 70–74 years, 5.1%; 65–69 years, 4.4%). In the CS group, time to conversion to AVR was similar across all age groups (median, 11 months; P =0.73). Approximately one-third of younger patients (65–69 years) in the CS arm presented with acute valve syndrome at the time of conversion, the frequency of which tended to increase with age ( P =0.06). CONCLUSIONS: In the EARLY TAVR trial, the relative benefit of early TAVR over CS was consistent among all age groups. The greatest absolute reduction in stroke rate with early TAVR compared with CS appeared in the youngest and oldest groups, whereas reduction in heart failure hospitalization was most pronounced in the oldest patients. These data suggest that early TAVR should be considered in all age groups above 65 years. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT03042104.
Virus-specific CD8 T cells rapidly populate and persist in skull bone marrow after brain infection
Johnson, Aaron , Hassani, Asma, Jin, Fang, Forston, Michael D. , Hadjimirzaei, Armeta, Lewis, Cody, Owens, Carley, Thelwell, Javonte, Maynes, Mark , Tian, Zichen, Hansen, Michael, Hassani, Asma , Hassani, Asma , Forston, Michael D , Lewis, Cody L, Thelwell, Javonte S. , Jin, Fang, Thelwell, Javonte , Seady, Marina , Maynes, Mark A , Ayasoufi, Katayoun

Mayo Clinic

No container title available | June 3, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-9890268/v1 | PMID 42281991 Get It

Abstract Skull bone marrow (BM) is a recently identified site for immune activation responsive to CNS insults. The extent to which adaptive immunity is generated through skull BM is poorly understood. In this study, we evaluated how skull BM supports the early expansion of antiviral CD8 T cells during acute neurotropic virus infection. Virus antigen-specific CD8 T cells were rapidly identified in skull BM at a rate comparable to lymphoid compartments during acute Theiler’s murine encephalomyelitis viral (TMEV) infection. We therefore employed MHC class I conditional knockout mice and demonstrated the necessity of CD11c+ antigen-presenting cells (APCs) for the generation of various subsets of TMEV-specific CD8 T cells in skull BM. Importantly, the early expansion of skull BM-derived antiviral T cells was impeded by FTY720 treatment and restored upon shared circulation with a mouse exhibiting intact antigen presentation by CD11c+ APCs. Additionally, TMEV-specific CD8 T cells were retained in skull BM during both chronic CNS infection and long after infection has been resolved. Overall, we determined that skull BM responds to acute neurotropic viral infection through the rapid recruitment of virus-specific CD8 T cells primed in the periphery before serving as a reservoir for immunologic memory.
Ziftomenib with venetoclax and azacitidine in relapsed/refractory NPM1-mutated acute myeloid leukemia
Wang, Eunice S. , Erba, Harry P. , Zeidan, Amer M., Roboz, Gail J. , Altman, Jessica, Advani, Anjali S. , Lin, Tara L. , Strickland, Stephen A. , Juckett, Mark , Pratz, Keith W., Mangan, James K. , McMahon, Christine M. , Alsfeld, Leonard Clarkson, Murthy, Guru Subramanian Guru, Rotta, Marcello, Palmisiano, Neil, McCloskey, James, Khawandanah, Mohamad, Naqvi, Kiran, Qasrawi, Ayman , Schiller, GJ, Badar, Talha, Gojo, Ivana , Yaghmour, George , Osman, Diaa, Zhang, Hongling, Tian, Ying, Soifer, Harris S., Riches, Marcie, Corum, Daniel, Leoni, Mollie, Fathi, Amir , Juckett, Mark , Saliba, Antoine N , Madanat, Yazan , Badar, Talha , Gojo, Ivana , Fathi, Amir T , Issa, Ghayas , Wang, Eunice S. , Erba, Harry Paul , Strickland, Stephen Anthony , Roboz, Gail J , Advani, Anjali S , Lin, Tara L , Zeidan, Amer M. , Altman, Jessica K. , Pratz, Keith W. , Alsfeld, Leonard C. , Balasubramanian, Suresh , Murthy, Guru Subramanian Guru , Palmisiano, Neil , McCloskey, James, Saliba, Antoine N. , Khawandanah, Mohamad , Madanat, Yazan F. , Naqvi, Kiran , Badar, Talha , Osman, Diaa , Zhang, Hongling, Soifer, Harris S. , Riches, Marcie , Corum, Daniel, Leoni, Mollie

Mayo Clinic

Blood Journal | June 2, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1182/blood.2026034043 | PMID 42227701 Get It

Ziftomenib - a potent, selective, oral menin inhibitor - is approved as monotherapy for adults with relapsed/refractory (R/R) NPM1-mutated acute myeloid leukemia (NPM1-m AML). The KOMET-007 phase 1 trial investigated clinical activity and tolerability of ziftomenib in combination with standard therapies for R/R and newly diagnosed AML. Here, we report outcomes of adults with R/R NPM1-m AML treated with ziftomenib plus venetoclax/azacitidine. In phase 1a, patients received ziftomenib 200, 400, or 600 mg once daily with standard doses of venetoclax/azacitidine. In phase 1b, ziftomenib 600 mg was selected for expansion. Sixty-seven patients were treated (27 phase 1a; 40 phase 1b). Median age was 66 years, and 55% were men. Median number of prior therapies was 1 (range 1-8); 55% received prior venetoclax and 22% had prior transplantation. Most common (≥20%) grade ≥3 treatment-emergent adverse events were leukopenia (34%), thrombocytopenia (28%), febrile neutropenia and neutropenia (25% each). Six patients developed QTc prolongation (1 ziftomenib-related; grade 1), and 2 experienced differentiation syndrome (grade 3); all events were successfully managed. In patients receiving ziftomenib 600 mg, composite complete remission (CRc) rate was 46% (22/48), with 67% (12/18) achieving central measurable residual disease (MRD) negativity (&lt;0.01% threshold). In venetoclax-naïve and -exposed patients, CRc rates were 70% (16/23) and 24% (6/25), with MRD-negativity rates of 75% (9/12) and 50% (3/6), respectively. Median duration of response was 8.6 months, and median overall survival was not reached. The combination of ziftomenib 600 mg with venetoclax/azacitidine was well tolerated with deep and durable clinical activity in R/R NPM1-m AML. This trial was registered at www.ClinicalTrials.gov as #NCT05735184.
Diagnostic Yield of Cardiac CT to Detect Cardiac Thrombi in Patients With Acute Ischemic Stroke (AIS of HEARTS)
Nio, Shan Sui , Green, Daniel S. , Berry-Noronha, Alexander , Rinkel, Leon A. , Beemsterboer, Chiel F.P. , Hasnain, Md Golam , Planken, R. Nils , Randen, Adriënne van , Al-Hadethi, Sinan , Hilt, Mirre G.M. , Ruhe, Deborah S.A., Boekholdt, S Matthijs, Chew, Beng Lim Alvin , Fridgant, Joshua, Mena-Romo, Luis , Kim, Dong Hyun, Guo, Shuyu, Winders, Joel, Senadeera, Sajith C. , Lim, Anthony , Fink, John, Leung, Melissa , Cordato, Dennis, Spratt, N., Collaborators, on behalf of the AIS of HEARTS, Green, Daniel S , van Randen, Adrienne , Bouma, Berto J , Boekholdt, S Matthijs , Fridgant, Joshua , Mena-Romo, Luis , Alamri, Yassar , Lim, Anthony T , Leung, Melissa , Cordato, Dennis , Parsons, Mark W , Spratt, Neil J , Garcia-Esperon, Carlos , Wu, Teddy Y , Coutinho, Jonathan M , Beemsterboer, Chiel F P , Planken, R Nils , Berry‐Noronha, Alexander , Hasnain, Md Golam , Hilt, Mirre , Ruhe, Deborah, Bouma, Berto J. , Boekholdt, S. Matthijs , Kim, Dong Hyun, Fink, John

Mayo Clinic

Stroke | June 2, 2026 | Volume: 57 | Issue: 8 | Pages: 2408-2416

10.1161/strokeaha.126.055575 | PMID 42227105 Get It

BACKGROUND: Cardiac computed tomography (CT) acquired during the acute stroke imaging protocol is an emerging modality to detect cardiac thrombi. We determined its yield in patients with acute ischemic stroke. METHODS: We performed a 1-stage individual patient data meta-analysis of 4 prospective observational cohorts (AIS of HEARTS [Acute Ischemic Stroke of Heart-Related Embolic Sources Detected on Acute Cardiac CT Scans]), including patients with acute ischemic stroke who underwent ECG-gated or non–ECG-gated cardiac CT between May 2018 and June 2024. We excluded patients with transient ischemic attack or stroke mimics. The primary outcome was the proportion of patients with a thrombus on cardiac CT. Secondary outcomes were additional scan time, radiation dose, comparison with echocardiography, and 90-day outcomes. We performed logistic regression analyses to compare 90-day outcomes between patients with and without thrombus, adjusting for age, sex, history of atrial fibrillation, ischemic heart disease, chronic heart failure, stroke or transient ischemic attack, anticoagulant use, prestroke modified Rankin Scale score, National Institutes of Health Stroke Scale score, large vessel occlusions, and intravenous thrombolysis, as appropriate for each outcome. RESULTS: We included 3919 patients (median age, 74 [interquartile range (IQR), 63–82], 58% male, median National Institutes of Health Stroke Scale score 6 [IQR, 3–12]). Cardiac CT detected a thrombus in 243 (6.2%) patients. Among 1323 patients that underwent both cardiac CT and transthoracic echocardiography, cardiac CT had a higher yield than transthoracic echocardiography (odds ratio, 7.4 [95% CI, 4.0–15.1]; P <0.001). Median additional scan time was 6 minutes (IQR, 5–7) for ECG-gated and 13 seconds (IQR, 12–61) for non–ECG-gated cardiac CT. Median additional radiation dose was 2.9 mSv (IQR, 1.6–4.1). Patients with thrombi had higher 90-day mortality (33% versus 15%, adjusted odds ratio, 1.6 [95% CI, 1.1–2.3]) and worse modified Rankin Scale scores (median modified Rankin Scale score 3 versus 2, adjusted odds ratio, 1.6 [95% CI, 1.2–2.0]), but similar recurrent stroke rates (5% versus 4%, adjusted odds ratio, 1.4 [95% CI, 0.7–2.5]). CONCLUSIONS: Implementing cardiac CT into the acute stroke imaging protocol is feasible, detects thrombi in ≈6% of patients, and has a higher yield than transthoracic echocardiography. Cardiac thrombi were associated with higher mortality, but not higher stroke recurrence. REGISTRATION: URL: https://www.clinicaltrials.gov ; Unique identifier: NCT07165093.
Enhanced Molecular Staging of Pancreatic Cancer Using Methylated DNA Markers in Peritoneal Lavage Fluid
Taylor, William R., Burger, Kelli N. , Maheshwari, Kalika , Kipp, Benjamin R. , Delgado, Adriana, Streich, Heather M., Cleary, S., Grotz, Travis E., Kendrick, Micheal L., Smoot, Rory L., Starlinger, Patrick P., Thiels, Cornelius A., Truty, Mark J., Warner, Susanne G., Majumder, Shounak, Mills, Krystal , Delgado, Adriana M, Grotz, Travis E , Berger, Calise K. , Taylor, William R. , Mahoney, Douglas W. , Doering, Karen A. , Foote, Patrick H. , Cleary, Sean P. , Grotz, Travis E. , Smoot, Rory L. , Starlinger, Patrick , Thiels, Cornelius A. , Truty, Mark J. , Warner, Susanne G. , Kisiel, John B. , Majumder, Shounak

Mayo Clinic

Journal of Surgical Oncology | June 2, 2026 | Volume: 134 | Issue: 2 | Pages: 257-262

10.1002/jso.70292 | PMID 42226556 Get It

ABSTRACT Background and Objectives Occult intra‐abdominal metastases are identified in approximately 20% of patients with radiographically localized pancreatic ductal adenocarcinoma (PDAC) through staging laparoscopy, as peritoneal cytology is limited in sensitivity. Methylated DNA markers (MDMs) have demonstrated high diagnostic accuracy for PDAC in tumor tissue, blood, and pancreatic secretions. This study assesses the feasibility and diagnostic performance of MDMs in peritoneal lavage fluid collected during staging laparoscopy, comparing their performance to mutant KRAS (m KRAS ) detection. Methods DNA from peritoneal lavage fluid of PDAC patients was analyzed for m KRAS mutations (codons 12, 13, and 61) using droplet‐digital PCR and for 13 MDMs and a reference gene (B3GALT6) using quantitative methylation‐specific PCR. An MDM score was generated from the average signal of the 13 MDMs and evaluated for its ability to detect intra‐abdominal metastases via receiver operator characteristic (ROC) analysis. Results Among 48 patients, 15 (31%) had intra‐abdominal metastases. The MDM score showed 87% sensitivity and 90% specificity (AUC = 0.98), outperforming m KRAS , which showed 40% sensitivity and 85% specificity (AUC = 0.62; p < 0.0001). Conclusions MDMs in peritoneal lavage fluid may enable highly accurate molecular staging of PDAC and warrant validation in larger studies.
Spinal cord imaging for multiple sclerosis: Advances, priorities, and opportunities
Laule, Cornelia , Cohen-Adad, Julien, Witt, Atlee , Luca, Gabriele C. De, Granziera, Cristina , Keegan, B. Mark , Kerbrat, Anne , Klawiter, Eric C, Kolind, Shannon , O’Grady, Kristin P. , Oh, Jiwon, Sivakolundu, Dinesh K. , Smith, Seth A, Vavasour, Irene M, Mainero, Caterina , Alonso-Ortiz, Eva, Krieger, Stephen , Li, David , Shinohara, Russell T, Henry, Roland G, Cooperative, North American Imaging in Multiple Sclerosis (NAIMS), Witt, Atlee A , De Luca, Gabriele C , Bagnato, Francesca R. , Gauthier, Susan A , Bakshi, Rohit , Beck, Erin S , Krieger, Stephen , Keegan, B Mark , Kollind, Shannon H , Granziera, Cristina , O'Grady, Kristin P , Cohen-Adad, Julien , DeLuca, Gabriele C. , Kerbrat, Anne , Klawiter, Eric C. , Oh, Jiwon , Schilling, Kurt G. , Smith, Seth A. , Tozlu, Ceren , Vavasour, Irene M. , Alonso‐Ortiz, Eva , Brier, Matthew R. , Hemond, Christopher C , Li, David K.B. , Shinohara, Russell Taki , Henry, Roland G.

Mayo Clinic

Multiple Sclerosis Journal | June 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/13524585261444600 | PMID 42224274 Get It

The spinal cord plays a central role in the pathophysiology and clinical manifestations of multiple sclerosis (MS), yet remains under-studied compared with the brain. This review summarizes key insights from the 2025 North American Imaging in MS Spinal Cord Imaging Workshop, highlighting recent advances, ongoing challenges, and future opportunities in MS spinal cord imaging. We review pathological studies and outline the clinical relevance of spinal cord lesions and atrophy for diagnosis, prognosis, and disease monitoring, highlighting emerging biomarkers of progression independent of relapse activity. Correlations between magnetic resonance imaging, histopathology, and clinical outcomes support the validation and translational potential of advanced spinal cord imaging techniques. Finally, we discuss spinal cord–specific processing pipelines and reproducibility challenges. Collectively, these insights underscore the need to integrate advanced and quantitative spinal cord imaging into clinical trials, research studies, and—when feasible—clinical care, to fully capture the extent of MS pathology, and ultimately improve patient outcomes.
Early Corticosteroid use and Clinical Outcomes in Patients with Mixed and Cardiogenic Shock
Gastanadui, Maria Gabriela , Murphy, Hannah R. , Shahu, Andi, Safiriyu, Israel , Heck, Cory, Hysolli, Maria, Garimella, Sanjana, Ali, Tariq , Jentzer, Jacob C., Gage, Ann, Katz, Jason N. , Miller, P. Elliott, Jentzer, Jacob C. , Jentzer, Jacob C , Miller, P Elliott , Gastanadui, Maria Gabriela , Safiriyu, Israel , Heck, Cory, Callegari, Santiago , Garimella, Sanjana , Gage, Ann , Jacobs, Mark , Miller, P. Elliott

Mayo Clinic

Journal of Intensive Care Medicine | June 1, 2026 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.1177/08850666261437767 | PMID 42223374 Get It

Background The pathophysiology of CS is complex and is associated with increased inflammation and impaired vascular tone. Corticosteroids are recommended in septic shock and have been proposed as a potential treatment for other types of shock. Objectives We sought to evaluate the clinical outcomes associated with early corticosteroid use in patients with cardiogenic shock (CS). Methods Using a nationally representative database including over 1000 hospitals, we identified adults ≥18 years of age admitted from 2015–2023 with a diagnosis of CS. Patients with adrenal insufficiency, chronic rheumatologic conditions, COVID-19 infection and acute COPD exacerbation were excluded. Using inverse probability treatment weighting (IPTW), we assessed for the association of receiving early corticosteroids (within the first 2 days of admission) versus no early corticosteroids and in-hospital mortality. Results Of the 167,721 identified patients with CS, the mean (SD) age was 65.5 (±15.2) years and 35.0% were women. A total of 13.2% received any corticosteroid within the first 2 days of admission. The most common corticosteroid was hydrocortisone (73.9%). Mortality for those receiving and not receiving early corticosteroids was 48.8% and 29.6% ( p < 0.001), respectively. After IPTW, early corticosteroid use remained associated with a 3.1% (95% confidence interval [CI]: 2.4% to 3.8%, p < 0.001) higher mortality. Among patients with CS and concomitant sepsis, 27.6% received early corticosteroids, which was similarly associated with a higher mortality (weighted mean 5.8% [95% CI: 4.6% to 7.0%, p < 0.001]). Conclusions Approximately 1 in 7 patients with CS received corticosteroids early during their admission, which was associated with higher in-hospital mortality.
Symbiotic-GI-03: A randomized, double-blind, phase 3 study of first-line PF-08634404, a PD-1/VEGF bispecific antibody, in combination with mFOLFOX6 in patients with metastatic colorectal cancer (mCRC).
Elez, E, Taieb, Julien, Xu, Rui-Hua, Taniguchi, Hiroya, Bekaii-Saab, Tanios S., Tie, Jeanne, Chalabi, Myriam , Chen, Zhiyu, Opneja, Aman, Kochenderfer, Mark D., Hong, Yong Sang , Richards, Donald A., Radecka, B., Clancy, Jill, Tonkovyd, Svitlana, Zhang, Xiaosong, Ng, Kimmie, Eng, Cathy , Élez, Elena , Taı̈eb, Julien , Xu, Rui‐Hua , Taniguchi, Hiroya , Bekaii‐Saab, Tanios , Tie, Jeanne , Chen, Zhiyu , Richards, D., Chen, Yiyi , Clancy, Jill S., Zhang, Xiaosong, Ng, Kimmie

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps3675 Get It

TPS3675 Background: Multi-agent chemotherapy regimens (eg, mFOLFOX6) ± anti-vascular endothelial growth factor (VEGF) or anti-epidermal growth factor regimens are currently the standard of care for patients (pts) with mCRC without targetable mutations. However, the 5-year survival rate remains low at approximately 16% (SEER, 2025). The addition of biological therapies (eg, bevacizumab [bev], an anti-VEGF monoclonal antibody) to immune checkpoint inhibitors (ICIs) has demonstrated a synergistic antitumor effect in solid tumors. However, ICI monotherapy has limited activity in mismatch repair proficient (pMMR)/microsatellite stable (MSS) mCRC. Simultaneous bispecific targeting of programmed death 1 (PD-1) and VEGF in conjunction with cytotoxic chemotherapy has the potential to enhance antitumor activity. PF-08634404 is a fully human immunoglobulin G4 (IgG4) bispecific antibody targeting PD-1 and VEGF. A phase 2 study of PF-08634404 with XELOX or mFOLFOX6 demonstrated promising antitumor activity with a manageable safety profile in first-line (1L) mCRC (Xu X, ESMO 2025; Abstract 796P). Methods: Symbiotic-GI-03 (NCT07222800) is an ongoing, double-blind, randomized, phase 3 study evaluating the efficacy and safety of 1L PF-08634404 + mFOLFOX6 vs bev + mFOLFOX6. Inclusion criteria are age ≥18 y; mCRC with measurable disease per RECIST 1.1; no prior systemic therapy for metastatic disease; ECOG PS 0 or 1; and adequate hematologic, hepatic, and renal function. Pts with BRAF V600E-mutant or mismatch repair deficient (dMMR)/microsatellite instability-high (MSI-H) CRC, active central nervous system metastases, or clinically significant risk of hemorrhage/fistula will be excluded. Approximately 800 pts will be randomized 1:1 to receive PF-08634404 + mFOLFOX6 or bev + mFOLFOX6 until disease progression, unacceptable toxicity, withdrawal of consent, or death. Randomization will be stratified by region (North America, Europe, or rest of world), RAS status (mutant or wildtype), and presence of liver metastasis (yes or no). The dual primary endpoints are progression-free survival (PFS) by blinded independent central review and overall survival; for each, a stratified log-rank test will be used to compare arms. Hazard ratios with corresponding 2-sided 95% CIs will be estimated using a stratified Cox proportional hazards model, and medians will be estimated using the Kaplan-Meier method with corresponding 2-sided 95% CIs calculated using the log(-log) method. Secondary endpoints include PFS by investigator, objective response rate, duration of response, PFS after next-line therapy, safety/tolerability, pharmacokinetics, immunogenicity, and patient-reported outcomes. Enrollment began in December 2025. Clinical trial information: NCT07222800 .
SARC045: A phase 2 trial of tebentafusp in HLA-A*02:01–positive patients with advanced clear cell sarcoma.
Agulnik, Mark, D'Angelo, Sandra P., Napolitano, Andrea , Ballman, Karla V. , Pollack, Seth M. , D'Angelo, Sandra P

Mayo Clinic

Journal of Clinical Oncology | May 28, 2026 | Volume: 44 | Issue: 16_suppl | Pages: No page available

10.1200/jco.2026.44.16_suppl.tps11591 Get It

TPS11591 Background: Tebentafusp (Kimmtrak) is a first-in-class bispecific T-cell engager, specifically a T-cell receptor (TCR)-anti-CD3 fusion protein, approved for HLA-A*02:01+ metastatic or unresectable uveal melanoma. Tebentafusp binds to the HLA-A02:01/gp100 peptide complexes on the tumour cell surface, recruiting polyclonal T cells, via CD3, to release cytokines and cytolytic mediators against the tumour. Clear cell sarcoma (CCS) is an ultra-rare soft-tissue sarcoma subtype with poor prognosis and limited therapeutic options. On histopathology, CCS is characterised by the expression of melanocytic antigens, including gp100. Methods: This Phase 2 trial evaluates the efficacy of Tebentafusp in HLA-A*02:01 positive patients with advanced CCS. Twenty-three patients will be treated with weekly I.V. infusion of Tebentafusp at the recommended dose until evidence of clinical benefit or patient withdrawal from study. Baseline and on-treatment biopsies, as well as longitudinal peripheral blood samples will be collected for translational analyses. Prospective data will also be collected from an observational non-comparative cohort of up to 24 patients with advanced CCS not eligible for the study due to incompatible HLA. Enrolment to the study has commenced in October 2025 in the US, with two currently active sites (Memorial Sloan Kettering Cancer Center and University of Southern California). One additional US site (Northwestern University) and one UK site (The Royal Marsden Hospital) are due to open. At the time of submission, 1 HLA-A*02:01 advanced CCS patient had started treatment with Tebentafusp. Clinical trial information: NCT06942442 .